Pentasa, 500 mg 50 pcs.

Pentasa is anti-inflammatory.

Pentasa reduces the formation of leukotrienes and cytokinins, neutralizes free radicals, inhibits leukocyte chemotaxis.

Indications

Non-specific ulcerative colitis; Crohn’s disease.

Active ingredient

Composition

1 tablet contains:

The active ingredient:

mesalazine500 mg;

Associates:

povidone;

ethylcellulose;

magnesium stearate;

talc;

MCC up to 750 mg.

How to take, the dosage

Overly, without chewing, if possible swallowed whole (for ease of swallowing it is divided into several parts or dissolved in water or juice just before intake), the dose is adjusted individually.

Adults, in worsening of ulcerative colitis or Crohn’s disease – usually up to 4 g/day in several doses; maintenance dose – 2 g/day in several doses in ulcerative colitis and 4 g/day in several doses in Crohn’s disease; children over 2 years – usually 20-30 mg/kg/day in several doses.

Interaction

Concomitant use of Pentas increases the hypoglycemic effect of sulfonylurea derivatives, the sensitivity of GCS, the toxicity of methotrexate and the effect of anticoagulants.

When used concomitantly, Pentas attenuates the activity of furosemide, spironolactone, sulfonamides, rifampicin.

When used concomitantly, Pentas increases the effectiveness of uricosuric drugs.

When used concomitantly, Pentas slows absorption of cyancobalamin.

Special Instructions

Treatment of patients with hepatic or renal dysfunction is possible only after evaluation of their degree of severity.

For the duration of treatment, and especially at the beginning of treatment, renal function (blood creatinine level) should be monitored regularly.

In case of suspected pericarditis, myocarditis and changes in blood count, treatment should be discontinued. The manifestations of the above-mentioned adverse reactions may be increased bleeding, subcutaneous hemorrhages, sore throat and fever if there are marked pathological changes in blood composition; fever and pain behind the chest combined with shortness of breath if pericarditis and/or myocarditis.

In some cases of allergic reactions to sulfasalazine it is possible to develop intolerance to the drug Pentasa as well (risk of allergy to salicylates).

Patients who are “slow acetylators” have an increased risk of developing side effects.

Possible staining of urine and tear fluid yellow-orange, staining of soft contact lenses.

Hypatic disorders: The drug is contraindicated in severe hepatic insufficiency.

Application in renal dysfunction: The use of the drug is contraindicated in severe renal failure.

Impact on ability to drive and operate machinery: The drug does not affect the ability to drive vehicles and operate machinery.

Contraindications

Hypersensitivity (including to salicylates or other components of the drug); marked liver and kidney function abnormalities.

Side effects

Perception of abdominal discomfort, nausea, vomiting, headache, diarrhea, skin rash in the form of urticaria or eczema;

Very rarely – pain in muscles and joints, temporary hair loss, liver and kidney function disorders, pericarditis, myocarditis, pancreatitis, changes in blood count (leukopenia, granulocytopenia, thrombocytopenia, anemia).

Overdose

Symptoms: nausea, vomiting, gastralgia, weakness, drowsiness.

Treatment: gastric lavage, administration of laxatives, symptomatic therapy.

Pregnancy use

In pregnancy and during lactation, prescribe only when the positive effect outweighs the risk of possible side effects.

Similarities